Literature DB >> 16880400

Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

Cullen M Taniguchi1, Thien T Tran, Tatsuya Kondo, Ji Luo, Kohjiro Ueki, Lewis C Cantley, C Ronald Kahn.   

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is central to the metabolic actions of insulin on liver. Here, we show that mice with a liver-specific deletion of the p85alpha regulatory subunit of PI3K (L-Pik3r1KO) exhibit a paradoxical improvement of hepatic and peripheral insulin sensitivity. Although PI3K enzymatic activity is diminished in L-Pik3r1KO livers because of a reduced level of regulatory and catalytic subunits of PI3K, insulin-stimulated Akt activity is actually increased. This increased Akt activity correlates with increased phosphatidylinositol (3,4,5)-trisphosphate levels which are due, at least in part, to diminished activity of the (3,4,5)-trisphosphate phosphatase PTEN. Thus, the regulatory subunit p85alpha is a critical modulator of insulin sensitivity in vivo not only because of its effects on PI3K activation, but also as a regulator of PTEN activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880400      PMCID: PMC1524929          DOI: 10.1073/pnas.0604628103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  DNA excision in liver by an albumin-Cre transgene occurs progressively with age.

Authors:  C Postic; M A Magnuson
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice.

Authors:  I Shimomura; M Matsuda; R E Hammer; Y Bashmakov; M S Brown; J L Goldstein
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

3.  Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.

Authors:  Kohjiro Ueki; Claudine M Yballe; Saskia M Brachmann; David Vicent; John M Watt; C Ronald Kahn; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

5.  Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

Authors:  Kohjiro Ueki; David A Fruman; Saskia M Brachmann; Yu-Hua Tseng; Lewis C Cantley; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

6.  Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes.

Authors:  Franck Mauvais-Jarvis; Kohjiro Ueki; David A Fruman; Michael F Hirshman; Kei Sakamoto; Laurie J Goodyear; Matteo Iannacone; Domenico Accili; Lewis C Cantley; C Ronald Kahn
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  Direct identification of PTEN phosphorylation sites.

Authors:  Susan J Miller; David Y Lou; David C Seldin; William S Lane; Benjamin G Neel
Journal:  FEBS Lett       Date:  2002-09-25       Impact factor: 4.124

8.  Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.

Authors:  D A Fruman; F Mauvais-Jarvis; D A Pollard; C M Yballe; D Brazil; R T Bronson; C R Kahn; L C Cantley
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

9.  Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta.

Authors:  Cullen M Taniguchi; Tatsuya Kondo; Mini Sajan; Ji Luo; Roderick Bronson; Tomoichiro Asano; Robert Farese; Lewis C Cantley; C Ronald Kahn
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

10.  Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction.

Authors:  M D Michael; R N Kulkarni; C Postic; S F Previs; G I Shulman; M A Magnuson; C R Kahn
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

View more
  73 in total

1.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Hydrogen sulfide and L-cysteine increase phosphatidylinositol 3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase (AKT)/protein kinase Cζ/λ (PKCζ/λ) in 3T3l1 adipocytes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

3.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Authors:  Lauren M Thorpe; Jennifer M Spangle; Carolynn E Ohlson; Hailing Cheng; Thomas M Roberts; Lewis C Cantley; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

4.  Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes.

Authors:  A Maharaj; L Zhu; F Huang; H Qiu; H Li; C Y Zhang; T Jin; Q Wang
Journal:  Diabetologia       Date:  2012-02-09       Impact factor: 10.122

5.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 6.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

7.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

8.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice.

Authors:  Jennifer W Hill; Kevin W Williams; Chianping Ye; Ji Luo; Nina Balthasar; Roberto Coppari; Michael A Cowley; Lewis C Cantley; Bradford B Lowell; Joel K Elmquist
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity.

Authors:  Yu-Hsin Chiu; Jennifer Y Lee; Lewis C Cantley
Journal:  Mol Cell       Date:  2014-03-20       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.